Alnylam's Heart Drug Still Shines
A new heart drug from Alnylam looks promising, even after another company's trial had problems.
Doctors want to help people with a special heart problem. This condition is called ATTR-CM. It makes the heart stiff and weak. Companies work hard to find good treatments for it.
AstraZeneca and Ionis recently had trouble with their drug for ATTR-CM. Their study did not go as planned. This news made some people worried about other drugs for this condition.
But experts say Alnylam's new drug is different. It is a next-generation treatment. This drug helps by silencing bad genes. It can still help patients, even those already taking other heart medicines. Many people believe Alnylam's drug offers a lot of hope.
This means that good treatments are still on the way for patients. It is important to keep watching how these new medicines develop.
Source: FierceBiotech
More from Biotech
